Molecular Partners Ag (MOLN) Capital Expenditures (2020 - 2025)

Molecular Partners Ag (MOLN) has reported Capital Expenditures for 6 consecutive years, with $894054.7 the latest figure, recorded in Q4 2025.

• Quarterly Capital Expenditures rose 11.0% year-over-year to $894054.7 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $916346.0 (up 11.77% YoY) and the FY2025 annual result came in at $893335.2, up 11.0% from the prior year.
• Capital Expenditures climbed to $894054.7 in Q4 2025 per MOLN's latest filing, from $679340.8 in the prior quarter.
• Over the last five years, Capital Expenditures for MOLN reached as high as $1.2 million in Q4 2022 and fell as low as -$656551.1 in Q2 2025.
• A 5-year average of $230908.0 and a median of $104755.7 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures jumped 274.38% — and 2025, when it slumped 256.5%.
• Year by year, Capital Expenditures stood at $1.0 million in 2021, then grew by 20.72% to $1.2 million in 2022, then plunged by 46.94% to $648541.1 in 2023, then advanced by 24.19% to $805422.4 in 2024, then rose by 11.0% to $894054.7 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $894054.7, $679340.8, and -$656551.1 for Q4 2025, Q3 2025, and Q2 2025 respectively.